Status | Study |
Recruiting |
Study Name: JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Condition: Primary Myelofibrosis Secondary Myelofibr Date: 2014-09-12 Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation |
Completed |
Study Name: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Condition: Primary Myelofibrosis (MF) Date: 2014-03-12 Interventions: Drug: Ruxolitinib |
Terminated |
Study Name: A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial) Condition: Primary Myelofibrosis Date: 2014-03-06 Interventions: Drug: Ruxolitinib Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. lo |
Active, not recruiting |
Study Name: Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis Condition: Myelofibrosis Date: 2012-12-24 Interventions: Drug: Peginterferon alfa-2a 50 mcg subcutaneous injection once per week |
Active, not recruiting |
Study Name: JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis Condition: Myelofibrosis Date: 2012-12-21 Interventions: Drug: Ruxolotinib Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT f |
Active, not recruiting |
Study Name: Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) Condition: Myelofibrosis Date: 2012-09-14 Interventions: Drug: Panobinostat PO TIW QOW |
Completed |
Study Name: A Phase 2 Study With IPI-926 in Patients With Myelofibrosis Condition: Primary Myelofibrosis Fibrosis, Bone Marrow Date: 2011-06-09 Interventions: Drug: IPI-926 Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive dise |
Completed |
Study Name: Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients Condition: Myelofibrosis Date: 2011-04-21 Interventions: Drug: Ruxolitinib Ruxolitinib was supplied as SR and IR formulated tablets. |
Completed |
Study Name: Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis Condition: Myelodysplastic Syndrome Primary Myelofibrosis Date: 2011-01-18 |
Active, not recruiting |
Study Name: Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence Condition: Primary Myelofibrosis Date: 2010-07-15 Interventions: Drug: Pomalidomide 0.5 mg Poma |